FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971291756> ?p ?o ?g. }

• W1971291756 abstract "Childhood and adolescent cancers are rare diseases. Despite the progress in treatment (more than two-thirds of all cases are cured), cancer remains the leading cause of death by disease in children older than 1 year. Access to new drugs that are more efficacious or better tolerated is therefore an important public health priority. The objective of our round table was thus to take inventory of the situation and to propose recommendations aimed at facilitating coordinated, rational and more rapid access to new treatments. The active participation of paediatric oncologists, parents, pharmaceutical companies and regulatory authorities proved not only necessary but very constructive. Pharmaceutical companies have developed very few new anticancer agents for children during the past 10 years. The round table identified current trends that appear propitious: the mobilisation of parents and patients' associations; European initiatives to encourage companies to assess drugs in children; regulatory initiatives to guide drug development; and the existence of structured clinical research networks in paediatric oncology, including for the development of early treatment. The round table recommends the following measures to improve access to new treatments for children and adolescents with cancer: 1. Conduct preclinical paediatric evaluation of all anticancer agents that begin the development process for adults (research and validation of treatment targets; pharmacological evaluation in relevant experimental models) to help choose the agents to study in children. 2. Initiate paediatric clinical development before the first application for authorization for adults is filed, when sufficient safety and tolerability data are available, that is, after the phase I trials in adults and optimally during the phase II trials. 3. Optimise paediatric clinical evaluation by defining development plans early and by reducing the duration of studies (enlargement of the early treatment research network to ensure adequate recruitment; new evaluation methods; better extrapolation of pharmacological data from adults to children for dose-finding). 4. Improve information to and participation of parents and patients in clinical research for new treatments. The prerequisite for the success of this project became rapidly clear to all the round-table participants: cooperation and partnership between specialists and other scientists from academia, parent associations, pharmaceutical companies and regulatory authorities. Only with such cooperation can progress in treatment occur and new hopes for recovery be fulfilled." @default.
• W1971291756 created "2016-06-24" @default.
• W1971291756 creator A5002047733 @default.
• W1971291756 creator A5002510169 @default.
• W1971291756 creator A5005457439 @default.
• W1971291756 creator A5005801556 @default.
• W1971291756 creator A5007701213 @default.
• W1971291756 creator A5009891337 @default.
• W1971291756 creator A5011992727 @default.
• W1971291756 creator A5012784279 @default.
• W1971291756 creator A5022216294 @default.
• W1971291756 creator A5024604492 @default.
• W1971291756 creator A5032668871 @default.
• W1971291756 creator A5034473496 @default.
• W1971291756 creator A5035417953 @default.
• W1971291756 creator A5035489207 @default.
• W1971291756 creator A5059899389 @default.
• W1971291756 creator A5060678091 @default.
• W1971291756 creator A5061120366 @default.
• W1971291756 creator A5063120070 @default.
• W1971291756 creator A5066708720 @default.
• W1971291756 creator A5067202962 @default.
• W1971291756 creator A5080254367 @default.
• W1971291756 creator A5083597593 @default.
• W1971291756 date "2003-05-01" @default.
• W1971291756 modified "2023-10-01" @default.
• W1971291756 title "Les essais cliniques en cancérologie pédiatrique" @default.
• W1971291756 cites W1596051841 @default.
• W1971291756 cites W1880913164 @default.
• W1971291756 cites W1963978907 @default.
• W1971291756 cites W1982150953 @default.
• W1971291756 cites W1991092971 @default.
• W1971291756 cites W2017470121 @default.
• W1971291756 cites W2064649463 @default.
• W1971291756 cites W2073678209 @default.
• W1971291756 cites W2074486658 @default.
• W1971291756 cites W2086489030 @default.
• W1971291756 cites W2094517517 @default.
• W1971291756 cites W2104263844 @default.
• W1971291756 cites W2115090035 @default.
• W1971291756 cites W2146762986 @default.
• W1971291756 cites W2156976216 @default.
• W1971291756 cites W2246273267 @default.
• W1971291756 cites W2467906760 @default.
• W1971291756 cites W63968789 @default.
• W1971291756 doi "https://doi.org/10.2515/therapie:2003037" @default.
• W1971291756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14655318" @default.
• W1971291756 hasPublicationYear "2003" @default.
• W1971291756 type Work @default.
• W1971291756 sameAs 1971291756 @default.
• W1971291756 citedByCount "5" @default.
• W1971291756 countsByYear W19712917562023 @default.
• W1971291756 crossrefType "journal-article" @default.
• W1971291756 hasAuthorship W1971291756A5002047733 @default.
• W1971291756 hasAuthorship W1971291756A5002510169 @default.
• W1971291756 hasAuthorship W1971291756A5005457439 @default.
• W1971291756 hasAuthorship W1971291756A5005801556 @default.
• W1971291756 hasAuthorship W1971291756A5007701213 @default.
• W1971291756 hasAuthorship W1971291756A5009891337 @default.
• W1971291756 hasAuthorship W1971291756A5011992727 @default.
• W1971291756 hasAuthorship W1971291756A5012784279 @default.
• W1971291756 hasAuthorship W1971291756A5022216294 @default.
• W1971291756 hasAuthorship W1971291756A5024604492 @default.
• W1971291756 hasAuthorship W1971291756A5032668871 @default.
• W1971291756 hasAuthorship W1971291756A5034473496 @default.
• W1971291756 hasAuthorship W1971291756A5035417953 @default.
• W1971291756 hasAuthorship W1971291756A5035489207 @default.
• W1971291756 hasAuthorship W1971291756A5059899389 @default.
• W1971291756 hasAuthorship W1971291756A5060678091 @default.
• W1971291756 hasAuthorship W1971291756A5061120366 @default.
• W1971291756 hasAuthorship W1971291756A5063120070 @default.
• W1971291756 hasAuthorship W1971291756A5066708720 @default.
• W1971291756 hasAuthorship W1971291756A5067202962 @default.
• W1971291756 hasAuthorship W1971291756A5080254367 @default.
• W1971291756 hasAuthorship W1971291756A5083597593 @default.
• W1971291756 hasBestOaLocation W19712917562 @default.
• W1971291756 hasConcept C138885662 @default.
• W1971291756 hasConcept C15708023 @default.
• W1971291756 hasConcept C17744445 @default.
• W1971291756 hasConcept C29456083 @default.
• W1971291756 hasConcept C71924100 @default.
• W1971291756 hasConceptScore W1971291756C138885662 @default.
• W1971291756 hasConceptScore W1971291756C15708023 @default.
• W1971291756 hasConceptScore W1971291756C17744445 @default.
• W1971291756 hasConceptScore W1971291756C29456083 @default.
• W1971291756 hasConceptScore W1971291756C71924100 @default.
• W1971291756 hasLocation W19712917561 @default.
• W1971291756 hasLocation W19712917562 @default.
• W1971291756 hasLocation W19712917563 @default.
• W1971291756 hasOpenAccess W1971291756 @default.
• W1971291756 hasPrimaryLocation W19712917561 @default.
• W1971291756 hasRelatedWork W1993695285 @default.
• W1971291756 hasRelatedWork W2047498965 @default.
• W1971291756 hasRelatedWork W2065038093 @default.
• W1971291756 hasRelatedWork W2129267808 @default.
• W1971291756 hasRelatedWork W2153957737 @default.
• W1971291756 hasRelatedWork W2319635624 @default.
• W1971291756 hasRelatedWork W2590183723 @default.
• W1971291756 hasRelatedWork W3027239688 @default.
• W1971291756 hasRelatedWork W3035677853 @default.

• next